Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ: ALT )

6.370 +0.140 (+2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,431,086
Open 6.220
Bid (Size) 6.420 (33)
Ask (Size) 6.440 (11)
Prev. Close 6.230
Today's Range 6.170 - 6.530
52wk Range 5.275 - 14.84
Shares Outstanding 71,124,625
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga

Performance

YTD
-10.41%
-10.41%
1 Month
-5.07%
-5.07%
3 Month
-10.91%
-10.91%
6 Month
-15.52%
-15.52%
1 Year
-27.28%
-27.28%

More News

Read More
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
Via Talk Markets
Topics Stocks / Equities
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Decoding 4 Analyst Evaluations For Altimmune
Via Benzinga
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024
Via InvestorPlace
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Via MarketBeat
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
3 Promising Biotech Stocks for the Long-Term: August 2024
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in August 2024
Via InvestorPlace
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Via The Motley Fool
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Via The Motley Fool
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Via The Motley Fool
3 Undervalued Biotech Stocks With Breakout Potential
Via InvestorPlace
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
Via InvestorPlace
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.